Pharmakey
Pharmakey

Who We Are...

Founder and CEO

David R. Houck Ph.D.

Dr. David Houck is an accomplished chemist and drug developer with over 25 years of experience in the pharmaceutical and biotechnology industries. Dr. Houck assists companies to find efficient and successful solutions to challenges of new drug products. His technical expertise is formulation development, manufacture, and quality control of their therapeutic candidates for preclinical and clinical studies. Dr. Houck has pharmaceutical and biotechnology experience at Merck, Sterling Winthrop, OSI Pharmaceuticals, and Scynexis, and has authored/co-authored over 25 articles, and holds ten patents.

President and Chief Drug Development Consultant

Christopher J. Pazoles Ph.D.

Dr. Pazoles has over 30 years of experience in drug discovery and development including IND enablement, pre-clinical to clinical translation and Phase I through Phase III clinical trials. He works with client companies to develop product strategies and design and execute programs to successfully advance products through scientific, regulatory and business milestones. Dr. Pazoles’ career includes large pharma (Pfizer, Abbott) as well as small biotech companies (Phytera, Novelos). He is the author/co-author of 50 scientific publications and holds two patents.

Director of Submissions

Robert Rohde B.S.

Mr. Rohde offers over 35 years of regulatory submission experience, including 15 years with electronic publishing systems such as Lorenz’s docuBridge. Beginning in 2004, Mr. Rohde supervised global publishing teams at multi-national pharmaceutical (Schwarz Biosciences) and clinical CRO (PPD) companies. Using the docuBridge system, he and his teams have assembled and published eCTD applications for multiple new chemical entities/biologic products to the FDA and EU authorities. They completed several hundred eCTD life cycle submissions resulting in product approvals in the US and EU. At Pharmakey, Robert oversees electronic publishing and submissions activities for numerous clients in support of INDs, NDAs, and ANDAs.